Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

DuP 785

Known as: DUP-785, DUP785 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

brequinarbrequinar sodium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
Enhancement of allograft survival by combination RS-61443 and DUP-785 therapy.
Current maintenance immunosuppressive therapy consists of cyclosporine in combination with prednisone and azathioprine… Expand
Is this relevant?
1992
1992
In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
Brequinar sodium (DUP-785; Brequinar) is a potent inhibitor of the pyrimidine de novo enzyme dihydroorotate dehydrogenase (DHO-DH… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • table I
Is this relevant?
1992
1992
Low-dose combination therapy of DUP-785 and RS-61443 prolongs cardiac allograft survival in rats.
The introduction of cyclosporine into the immunosuppressive armamentarium has revolutionized transplant surgery with significant… Expand
Is this relevant?
1990
1990
In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Little is known about the in vivo effects of inhibition of the mitochondrial pyrimidine de novo synthesis enzyme dihydroorotic… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
1990
1990
Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Brequinar sodium (DUP-785) is a potent inhibitor of the pyrimidine de novo enzyme, dihydroorotic acid dehydrogenase (DHO-DH). In… Expand
Is this relevant?
1990
1990
Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.
The effect of Brequinar sodium on the growth of xenografts established from head and neck squamous cell carcinomas (HNSCC) was… Expand
Is this relevant?
1990
1990
Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC.
 
Is this relevant?
1989
1989
Cellular pharmacology of DUP-785, a new anticancer agent.
DUP-785, a new inhibitor of dihydroorotate dehydrogenase, is currently undergoing clinical evaluation for anticancer activity. We… Expand
Is this relevant?
1987
1987
Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)
The mechanism of action of NSC 368390 (DUP-785, 6-fluoro-2-(2′-fluoro-1, 1′-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1985
1985
Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.
A novel, substituted 4-quinolinecarboxylic acid (NSC 339768) demonstrated antitumor activity against L1210 leukemia and B16… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE